Common Sites for Local Infections with Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis, increases risk of local infections at injection sites due to its subcutaneous administration. These typically occur where the drug is injected, as the needle punctures skin and the immunosuppressive effect can promote bacterial entry.[1]
Primary Injection Sites Affected
Patients self-administer Cosentyx via pre-filled syringes or autoinjectors into:
- Front of thighs
- Abdomen (at least 2 inches from navel)
- Upper outer arms (by caregiver)
Local infections like cellulitis, abscesses, or erythema most often develop at these spots, with thigh and abdomen sites reported most frequently in trials.[2][3]
Why These Areas and Risk Factors
Skin in these regions is thinner or more mobile, making it prone to micro-tears during injection. Poor hygiene, improper rotation of sites, or underlying skin conditions (e.g., psoriasis plaques) heighten risk. Clinical data show infections in 1-3% of patients, usually mild and resolving with antibiotics.[2]
How to Spot and Prevent Local Infections
Watch for redness, swelling, warmth, pus, or pain at the site within days of injection. Rotate sites, clean skin with alcohol swabs, and avoid injecting into irritated areas. Severe cases may require stopping treatment.[3]
Related Infection Risks Beyond Injection Sites
Cosentyx also raises candida infections (oral, esophageal, genital) due to immune modulation, but these are not 'local' to injection. Upper respiratory and urinary tract infections occur more broadly.[2]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: DrugPatentWatch.com - Cosentyx Adverse Events